KIRKLAND, QC, Oct. 1, 2018 /CNW Telbec/ - Manitex Capital
Inc. ("Manitex") (TSXV: MNX) is pleased to announce that its affiliate, Valeo Pharma Inc. ("Valeo Pharma"), has filed a
non-offering preliminary prospectus with the securities regulatory authorities of all provinces and territories in Canada.
The non-offering prospectus is being filed for the purpose of allowing Valeo Pharma to become a reporting issuer in all
jurisdictions of Canada and to become eligible for listing pursuant to the policies of the TSX
Venture Exchange ("TSXV"). Listing will be subject to Valeo Pharma fulfilling all of the listing requirements of the TSXV.
The preliminary prospectus can be found on SEDAR at www.sedar.com.
Caution regarding forward-looking statements
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events.
Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions
prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this
press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and
other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements,
whether as a result of new information, future events or otherwise, other than as required by security laws.
About Manitex Capital Inc.
Manitex Capital Inc. invests in promising emerging companies from diversified sectors including life sciences, cleantech and
sustainable products/technologies. Manitex provides its portfolio companies with specialized corporate finance and advisory
services including corporate strategy, mergers and acquisitions, public markets access and financing. Manitex currently has
12,561,276 common shares outstanding which are quoted for trading on the TSX Venture Exchange, symbol MNX.V.
About Valeo Pharma Inc.
Valeo Pharma is a specialty pharmaceutical company dedicated to the acquisition, in-licensing and launch of innovative
prescription products in Canada. With a focus on neurodegenerative diseases, woman's health and rare diseases, Valeo Pharma
has a growing portfolio of innovative products and a platform to properly manage these products through all stages of
commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all
capabilities internally to register and market health care solutions for Canadian patients. For more information, please
visit www.valeopharma.com.
TSX Venture Exchange nor its Regulation Services Provider (as that termis defined in the policies of the TSX Venture Exchange)
accept responsibility for the adequacy or accuracy of this release.
SOURCE Manitex Capital Inc.
View original content: http://www.newswire.ca/en/releases/archive/October2018/01/c8765.html